NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 12, 2024. If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of ...

SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the “Class Period”). Captioned Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (N.D. Cal.), the Akero class action lawsuit charges Akero as well as certain of its top executives with violations of the Sec ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ:AKRO) and reminds investors of the June 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) and reminds investors of the June 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ...

SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin (EFX) in patients with compensated cirrhosis, fibrosis stage 4 (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). "Patie ...

SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin (EFX) in patients with compensated cirrhosis, fibrosis stage 4 (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). “Pati ...

SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with serious metabolic disorders marked by high unmet medical need, today announced two presentations featuring its lead product candidate efruxifermin (EFX) at the European Association for the Study of the Liver (EASL) Congress 2024, in Milan, Italy. The presentations will also be available on Akero's website follow ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc. ("Akero" or the “Company”) (NASDAQ: AKRO) investors that a class action has been filed on behalf of investors. Akero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoyl ...

NEW YORK, June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO) and reminds investors of the June 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero ...

NEW ORLEANS, June 05, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company’s shares between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Califo ...